BRAF and melanoma: As a consequence of our results, patients with high eTILs and a relevant risk of relapse (IIB and above) or advanced melanoma patients (stage III/IV) should receive anti-PD-1 therapy for both BRAF wild type and BRAF-mutated melanoma.